IMV Shares outstanding
What is the Shares outstanding of IMV?
The Shares outstanding of IMV, Inc. is 8.237M
What is the definition of Shares outstanding?
Shares outstanding are all the shares of a corporation or of a financial asset that have been authorized, issued and purchased by investors and are held by them.
= issued shares - treasury shares
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
Shares outstanding of companies in the Health Care sector on TSX compared to IMV
What does IMV do?
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Companies with shares outstanding similar to IMV
- LifeSci Acquisition has Shares outstanding of 8.205M
- Deal Pro Capital Corp has Shares outstanding of 8.207M
- Vivoryon Therapeutics AG has Shares outstanding of 8.208M
- Kuros Biosciences AG has Shares outstanding of 8.209M
- Buzz Capital 2 has Shares outstanding of 8.220M
- Devoteam SA has Shares outstanding of 8.226M
- IMV has Shares outstanding of 8.237M
- Prithvi Exchange (India) has Shares outstanding of 8.250M
- California BanCorp has Shares outstanding of 8.251M
- Cavco Industries Inc has Shares outstanding of 8.253M
- Titan Biotech has Shares outstanding of 8.264M
- Enertime SA has Shares outstanding of 8.266M
- CRCAM Paris & Ile de France has Shares outstanding of 8.267M